Expanded Access

FDA Grants Expanded Early Access to Breakthrough Pancreatic Cancer Drug Daraxonrasib

The U.S. FDA approves expanded access to daraxonrasib, a breakthrough targeted therapy for previously treated metastatic pancreatic ductal adenocarcinoma, offering new hope for patients with one of the deadliest cancers.

FDA Grants Expanded Early Access to Pancreatic Cancer Drug Daraxonrasib

The U.S. FDA approves expanded early access for the experimental pancreatic cancer drug daraxonrasib, offering new hope for late-stage patients.